Our Pipeline

Our determination to find answers for patients and their families motivates us to pursue medicines and vaccines with the greatest potential to improve lives and protect public health. With a strong focus on difficult-to-treat diseases and immunization, our R&D pipeline includes 78 clinical-stage projects, 33 of which are in phase 3 or have been submitted to regulatory authorities for approval. Some of these are new molecular entities while others are existing products with potential new indications, or different formulations. All of them are made possible by people who volunteer to participate in a clinical trial.

Phase 1
14
Phase 2
31
Phase 3
29
Registration
4

Search for a specific a clinical-stage projects

All therapeutic areas
All phases
All expected timeline
78 project(s) of 78
Therapeutic Area
Phase
Name
Description
Indication

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR444336

Phase

1
2
3
R

Description

Non-beta IL2 Synthorin™

Indication

Inflammatory indication

Inflammatory indication

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR445399

Phase

1
2
3
R

Description

IL1R3 mAb

Indication

Inflammatory indication

Inflammatory indication

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR445611

Phase

1
2
3
R

Description

CX3CR1 Nanobody® VHH

Indication

Inflammatory indication

Inflammatory indication

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR446422

Phase

1
2
3
R

Description

CD28/OX40 bispecific Ab

Indication

Inflammatory indication

Inflammatory indication

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb
New phase

Indication

Systemic sclerosis

New phase

Systemic sclerosis

New phase

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb
New phase

Indication

Alopecia areata

New phase

Alopecia areata

New phase

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb

Indication

Hidradenitis suppurativa

Hidradenitis suppurativa

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb

Indication

Asthma

Asthma

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent®

Phase

1
2
3
R

Description

IL4/IL13 mAb

Indication

Ulcerative colitis

Ulcerative colitis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

duvakitug

Phase

1
2
3
R

Description

TL1A mAb

Indication

Crohn's disease

Crohn's disease

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

duvakitug

Phase

1
2
3
R

Description

TL1A mAb

Indication

Ulcerative colitis

Ulcerative colitis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

eclitasertib

Phase

1
2
3
R

Description

RIPK1 inhibitor

Indication

Ulcerative colitis

Ulcerative colitis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

CD40L mAb

Indication

Type 1 diabetes

Type 1 diabetes

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

CD40L mAb

Indication

Systemic lupus erythematosus

Systemic lupus erythematosus

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

itepekimab

Phase

1
2
3
R

Description

IL33 mAb

Indication

Bronchiectasis

Bronchiectasis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

lunsekimig

Phase

1
2
3
R

Description

IL13/TSLP Nanobody® VHH

Indication

Asthma

Asthma

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

riliprubart

Phase

1
2
3
R

Description

C1s inhibitor

Indication

Antibody-mediated rejection

Antibody-mediated rejection

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Chronic spontaneous urticaria

Chronic spontaneous urticaria

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Asthma

Asthma

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

IgG4-related disease

IgG4-related disease

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR441566

Phase

1
2
3
R

Description

Oral TNFR1 signaling inhibitor

Indication

Rheumatoid arthritis

Rheumatoid arthritis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR441566

Phase

1
2
3
R

Description

Oral TNFR1 signaling inhibitor

Indication

Psoriasis

Psoriasis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR442970

Phase

1
2
3
R

Description

TNFa/OX40L Nanobody® VHH

Indication

Hidradenitis suppurativa

Hidradenitis suppurativa

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR444656

Phase

1
2
3
R

Description

IRAK4 degrader

Indication

Hidradenitis suppurativa

Hidradenitis suppurativa

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR444656

Phase

1
2
3
R

Description

IRAK4 degrader

Indication

Atopic dermatitis

Atopic dermatitis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb

Indication

Atopic dermatitis

Atopic dermatitis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent®

Phase

1
2
3
R

Description

IL4/IL13 mAb

Indication

Chronic spontaneous urticaria (US)

Chronic spontaneous urticaria (US)

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent®

Phase

1
2
3
R

Description

IL4/IL13 mAb

Indication

Eosinophilic gastritis

Eosinophilic gastritis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent®

Phase

1
2
3
R

Description

IL4/IL13 mAb

Indication

Bullous pemphigoid

Bullous pemphigoid

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent®

Phase

1
2
3
R

Description

IL4/IL13 mAb

Indication

Chronic pruritis of unknown origin

Chronic pruritis of unknown origin

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

itepekimab

Phase

1
2
3
R

Description

IL33 mAb

Indication

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Rezurock®

Phase

1
2
3
R

Description

ROCK2 inhibitor

Indication

1L chronic graft versus host disease

1L chronic graft versus host disease

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Rezurock®

Phase

1
2
3
R

Description

ROCK2 inhibitor

Indication

Chronic lung allograft dysfunction

Chronic lung allograft dysfunction

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Tzield™

Phase

1
2
3
R

Description

CD3 mAb

Indication

Type 1 diabetes

Type 1 diabetes

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent®

Phase

1
2
3
R

Description

IL4/IL13 mAb

Indication

Chronic obstructive pulmonary disease (US, JP, CN)

Chronic obstructive pulmonary disease (US, JP, CN)

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent®

Phase

1
2
3
R

Description

IL4/IL13 mAb
New phase

Indication

Chronic spontaneous urticaria (EU)

New phase

Chronic spontaneous urticaria (EU)

New phase

Therapeutic Area

Neurology

1
2
3
R

Name

SAR446159

Phase

1
2
3
R

Description

Synuclein/IGF1R mAb

Indication

Parkinson's disease

Parkinson's disease

Therapeutic Area

Neurology

1
2
3
R

Name

oditrasertib

Phase

1
2
3
R

Description

RIPK1 inhibitor

Indication

Multiple sclerosis

Multiple sclerosis

Therapeutic Area

Neurology

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

CD40L mAb

Indication

Non-relapsing secondary progressive MS

Non-relapsing secondary progressive MS

Therapeutic Area

Neurology

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

CD40L mAb

Indication

Relapsing multiple sclerosis

Relapsing multiple sclerosis

Therapeutic Area

Neurology

1
2
3
R

Name

riliprubart

Phase

1
2
3
R

Description

C1s inhibitor
New phase

Indication

IVIg-treated CIDP

New phase

IVIg-treated CIDP

New phase

Therapeutic Area

Neurology

1
2
3
R

Name

riliprubart

Phase

1
2
3
R

Description

C1s inhibitor
New phase

Indication

SOC-refractory CIDP

New phase

SOC-refractory CIDP

New phase

Therapeutic Area

Neurology

1
2
3
R

Name

tolebrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Non-relapsing secondary progressive MS

Non-relapsing secondary progressive MS

Therapeutic Area

Neurology

1
2
3
R

Name

tolebrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Primary progressive MS

Primary progressive MS

Therapeutic Area

Neurology

1
2
3
R

Name

tolebrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Relapsing multiple sclerosis

Relapsing multiple sclerosis

Therapeutic Area

Oncology

1
2
3
R

Name

pegenzileukin

Phase

1
2
3
R

Description

Non-alpha IL2 Synthorin™

Indication

Cancer, in combination

Cancer, in combination

Therapeutic Area

Oncology

1
2
3
R

Name

SAR444200

Phase

1
2
3
R

Description

GPC3/TCR Nanobody® VHH

Indication

Solid tumors

Solid tumors

Therapeutic Area

Oncology

1
2
3
R

Name

SAR444881

Phase

1
2
3
R

Description

ILT2 mAb

Indication

Solid tumors

Solid tumors

Therapeutic Area

Oncology

1
2
3
R

Name

SAR445514

Phase

1
2
3
R

Description

Trifunctional anti-BCMA NK cell engager

Indication

Relapsed/refractory multiple myeloma

Relapsed/refractory multiple myeloma

Therapeutic Area

Oncology

1
2
3
R

Name

SAR445877

Phase

1
2
3
R

Description

PD1/IL15 fusion protein

Indication

Solid tumors

Solid tumors

Therapeutic Area

Oncology

1
2
3
R

Name

SAR445953

Phase

1
2
3
R

Description

CEACAM5/Topo1 ADC

Indication

Colorectal cancer

Colorectal cancer

Therapeutic Area

Oncology

1
2
3
R

Name

SAR443579

Phase

1
2
3
R

Description

Trifunctional anti-CD123 NK cell engager
New phase

Indication

Acute myeloid leukemia

New phase

Acute myeloid leukemia

New phase

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa®

Phase

1
2
3
R

Description

CD38 mAb

Indication

Multiple myeloma, relapsed/refractory

Multiple myeloma, relapsed/refractory

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa®

Phase

1
2
3
R

Description

CD38 mAb

Indication

Multiple myeloma, 1L TE (IsKia)

Multiple myeloma, 1L TE (IsKia)

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa®

Phase

1
2
3
R

Description

CD38 mAb subcutaneous

Indication

Multiple myeloma, relapsed/refractory (IRAKLIA)

Multiple myeloma, relapsed/refractory (IRAKLIA)

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa®

Phase

1
2
3
R

Description

CD38 mAb

Indication

Smoldering multiple myeloma (ITHACA)

Smoldering multiple myeloma (ITHACA)

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa®

Phase

1
2
3
R

Description

CD38 mAb

Indication

Multiple myeloma, 1L TE (HD7)

Multiple myeloma, 1L TE (HD7)

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa®

Phase

1
2
3
R

Description

CD38 mAb

Indication

Multiple myeloma, 1L TI (IMROZ) (US, EU, JP, CN)

Multiple myeloma, 1L TI (IMROZ) (US, EU, JP, CN)

Therapeutic Area

Rare Diseases

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Warm autoimmune hemolytic anemia

Warm autoimmune hemolytic anemia

Therapeutic Area

Rare Diseases

1
2
3
R

Name

SAR447537

Phase

1
2
3
R

Description

AAT fusion protein
New

Indication

Alpha-1 antitrypsin deficiency

New

Alpha-1 antitrypsin deficiency

New

Therapeutic Area

Rare Diseases

1
2
3
R

Name

losmapimod

Phase

1
2
3
R

Description

p38α/β MAPK inhibitor
New

Indication

Facioscapulohumeral muscular dystrophy

New

Facioscapulohumeral muscular dystrophy

New

Therapeutic Area

Rare Diseases

1
2
3
R

Name

Nexviazyme®

Phase

1
2
3
R

Description

Enzyme replacement therapy

Indication

Pompe disease, infantile onset (US)

Pompe disease, infantile onset (US)

Therapeutic Area

Rare Diseases

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Immune thrombocytopenia

Immune thrombocytopenia

Therapeutic Area

Rare Diseases

1
2
3
R

Name

venglustat

Phase

1
2
3
R

Description

Oral GCS inhibitor

Indication

Fabry disease

Fabry disease

Therapeutic Area

Rare Diseases

1
2
3
R

Name

venglustat

Phase

1
2
3
R

Description

Oral GCS inhibitor

Indication

Gaucher disease type 3

Gaucher disease type 3

Therapeutic Area

Rare Diseases

1
2
3
R

Name

fitusiran

Phase

1
2
3
R

Description

RNAi targeting anti-thrombin
New phase

Indication

Hemophilia A and B (US, CN)

New phase

Hemophilia A and B (US, CN)

New phase

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0237

Phase

1
2
3
R

Description

Flu mRNA vaccine
New

Indication

Flu

New

Flu

New

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0256

Phase

1
2
3
R

Description

RSV mRNA combination vaccine

Indication

RSV older adult

RSV older adult

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0268

Phase

1
2
3
R

Description

Acne mRNA vaccine
New

Indication

Acne

New

Acne

New

Therapeutic Area

Vaccines

1
2
3
R

Name

Fluzone® HD

Phase

1
2
3
R

Description

Influenza inactivated vaccine

Indication

Flu, pediatric

Flu, pediatric

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0202

Phase

1
2
3
R

Description

Pneumococcal 21-valent conjugate vaccine

Indication

Pneumococcal disease

Pneumococcal disease

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0218

Phase

1
2
3
R

Description

Yellow fever vero cell vaccine

Indication

Yellow fever

Yellow fever

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0230

Phase

1
2
3
R

Description

Pentavalent meningococcal ABCWY conjugate vaccine
New phase

Indication

Meningitis

New phase

Meningitis

New phase

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0256

Phase

1
2
3
R

Description

RSV mRNA vaccine

Indication

RSV older adult

RSV older adult

Therapeutic Area

Vaccines

1
2
3
R

Name

MenQuadfi

Phase

1
2
3
R

Description

Meningococcal ACYW conjugate vaccine

Indication

Meningitis six weeks+

Meningitis six weeks+

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0087

Phase

1
2
3
R

Description

Rabies vero cell vaccine

Indication

Rabies

Rabies

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0125

Phase

1
2
3
R

Description

RSV live attenuated vaccine

Indication

Respiratory syncytial virus (toddler)

Respiratory syncytial virus (toddler)

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0282

Phase

1
2
3
R

Description

Extraintestinal Pathogenic E. Coli 9-valent vaccine (ExPEC9V)

Indication

Invasive ExPEC disease

Invasive ExPEC disease

Program Updates

The following changes occurred in our R&D programs.

Updated on July 25, 2024

Therapeutic Area
Phase
Name
Description
Additional Details

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb Indication: Systemic sclerosis

Additional Details

See our quarterly earnings press release, issued on July 25, 2024

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb Indication: Alopecia areata

Additional Details

See our quarterly earnings press release, issued on July 25, 2024

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor Indication: Asthma

Additional Details

See our quarterly earnings press release, issued on July 25, 2024

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent®

Phase

1
2
3
R

Description

IL4/IL13 mAb Indication: Chronic obstructive pulmonary disease (US, JP, CN)

Additional Details

See our quarterly earnings press release, issued on July 25, 2024

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent®

Phase

1
2
3
R

Description

IL4/IL13 mAb Indication: Chronic spontaneous urticaria (EU)

Additional Details

See our quarterly earnings press release, issued on July 25, 2024

Therapeutic Area

Neurology

1
2
3
R

Name

riliprubart

Phase

1
2
3
R

Description

C1s inhibitor Indication: IVIg-treated CIDP

Additional Details

See our quarterly earnings press release, issued on July 25, 2024

Therapeutic Area

Neurology

1
2
3
R

Name

riliprubart

Phase

1
2
3
R

Description

C1s inhibitor Indication: SOC-refractory CIDP

Additional Details

See our quarterly earnings press release, issued on July 25, 2024

Therapeutic Area

Oncology

1
2
3
R

Name

SAR443579

Phase

1
2
3
R

Description

Trifunctional anti-CD123 NK cell engager Indication: Acute myeloid leukemia

Additional Details

See our quarterly earnings press release, issued on July 25, 2024

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa®

Phase

1
2
3
R

Description

CD38 mAb Indication: Multiple myeloma, 1L TI (IMROZ) (US, EU, JP, CN)

Additional Details

See our quarterly earnings press release, issued on July 25, 2024

Therapeutic Area

Rare Diseases

1
2
3
R

Name

SAR442501

Phase

1
2
3
R

Description

Anti-FGFR3 antibody Indication: Achondroplasia

Additional Details

See our quarterly earnings press release, issued on July 25, 2024

Therapeutic Area

Rare Diseases

1
2
3
R

Name

SAR447537

Phase

1
2
3
R

Description

AAT fusion protein Indication: Alpha-1 antitrypsin deficiency

Additional Details

See our quarterly earnings press release, issued on July 25, 2024

Therapeutic Area

Rare Diseases

1
2
3
R

Name

Iosmapimod

Phase

1
2
3
R

Description

p38α/β MAPK inhibitor Indication: Facioscapulohumeral muscular dystrophy

Additional Details

See our quarterly earnings press release, issued on July 25, 2024

Therapeutic Area

Rare Diseases

1
2
3
R

Name

fitusiran

Phase

1
2
3
R

Description

RNAi targeting anti-thrombin Indication: Hemophilia A and B (US, CN)

Additional Details

See our quarterly earnings press release, issued on July 25, 2024

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0237

Phase

1
2
3
R

Description

Flu mRNA vaccine Indication: Flu

Additional Details

See our quarterly earnings press release, issued on July 25, 2024

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0268

Phase

1
2
3
R

Description

Acne mRNA vaccine Indication: Acne

Additional Details

See our quarterly earnings press release, issued on July 25, 2024

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0230

Phase

1
2
3
R

Description

Pentavalent meningococcal ABCWY conjugate vaccine Indication: Meningitis

Additional Details

See our quarterly earnings press release, issued on July 25, 2024

Therapeutic Area

Vaccines

1
2
3
R

Name

MenQuadfi

Phase

1
2
3
R

Description

Meningococcal ACYW conjugate vaccine Indication: Meningitis six weeks+

Additional Details

See our quarterly earnings press release, issued on July 25, 2024

Related Links

Research & Development

See more

Technology Platforms

See more

Clinical trials & results

See more